Drug
Bnt113
Bnt113: highest development phase Phase 2/3, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT113 NCT04534205 | Phase 2/3 | Unresectable Head and Neck Squamous Cell Carcinoma |
Latest
No recent events.
Follow Bnt113 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.